1. Home
  2. |Insights
  3. |PODCAST: The Future of Chevron Deference — C&M's Trump: The First Year Series

PODCAST: The Future of Chevron Deference — C&M's Trump: The First Year Series

Client Alert | 1 min read | 08.22.17

In the latest podcast for Crowell & Moring’s “Trump: The First Year” series, David Chung, partner in the firm’s Environment & Natural Resources Group, and Carlton Greene, partner in the International Trade Group, sit down to discuss the future of Chevron deference and how that doctrine relates to the Trump administration's goal of deconstructing the administrative state. Prior to joining the firm in 2015, Carlton served as chief counsel of FinCEN and also worked for OFAC at the Dept. of the Treasury. David’s practice focuses on litigation and regulatory counseling involving natural resources development and environmental issues.

Covered in this 22-minute podcast:

  • An overview of Chevron deference and recent developments.
  • How much flexibility and power agencies have when invoking Chevron deference.
  • The future of Chevron deference. 
  • Possible implications of eliminating Chevron deference. 

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Contacts

Insights

Client Alert | 3 min read | 06.26.25

FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”

In a somewhat ambiguous press release on Wednesday, June 18, 2025, the Food and Drug Administration (FDA) announced a halt and “immediate review” of new clinical trials where American patients’ cells are sent to China or other “hostile countries” for genetic engineering with the expectation that the cells will be infused back into U.S. patients.[1] A subsequent podcast published by the agency also said that therapies that involved cells that were sent to China for genetic engineering and intended for subsequent infusion into U.S. patients would not be approved going forward. The announcement said that there is “mounting evidence” that some clinical researchers failed to obtain informed consent from trial participants about the international transfer and manipulation of biological material....

View All Insights